AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

1.-5. (Canceled)

6. (Previously Presented) A composition for the inhibition of the translation of a Mect1-MAML2 chimeric gene, consisting essentially of: (a) a fragment of a nucleic acid encoding SEQ ID NO: 12 and (b) a nucleic acid complementary to the fragment, optionally comprising 1 to 3 substitutions, wherein the fragment of a nucleic acid encoding SEQ ID NO: 12 comprises the nucleotide sequence of SEQ ID NO: 5 or 6.

7. (Canceled)

8. (Previously Presented) The composition of claim 6, wherein the fragment of a nucleic acid encoding SEQ ID NO: 12, the nucleic acid complementary to the fragment, or both are in a vector.

9. (Original) The composition of claim 8, wherein the vector is a plasmid.

10. (Original) The composition of claim 8, wherein the vector is a viral vector.

11. (Original) The composition of claim 10, wherein the viral vector is an adenoviral vector.

12.-15. (Canceled)

16. (Previously Presented) A composition for the inhibition of the translation of a Mect1-MAML2 chimeric gene, consisting essentially of nucleic acid comprising the nucleotide sequence of SEQ ID NO: 2, 3, or 4.

17.-19. (Canceled)

20. (Previously Presented) The composition of claim 6, wherein the fragment of a nucleic acid encoding SEQ ID NO: 12 and the nucleic acid complementary to the fragment are under the control of different promoters on the same nucleic acid molecule.

21. (Original) The composition of claim 20, wherein the promoters are RNA polymerase promoters.

22. (Original) The composition of claim 21, wherein the promoters are RNA polymerase III promoters.

23.-46. (Canceled)

47. (Previously Presented) A method of inhibiting the translation of a Mect1-MAML2 chimeric gene in a cell comprising contacting the cell expressing the Mect1-MAML2 chimeric gene with the composition of claim 6, whereupon the translation of the Mect1-MAML2 chimeric gene in the cell is inhibited.

48. (Previously Presented) The method of claim 47, wherein the cell comprises a t(11;19) translocation, wherein the translocation results in a Mect1-MAML2 chimeric gene.

49. (Previously Presented) The method of claim 47, wherein the cell is in a host.

50. (Previously Presented) The method of claim 49, wherein the host is a mammal.

51. (Previously Presented) The method of claim 50, wherein the mammal is a human.

52. (Previously Presented) The method of claim 50, wherein the cell is a cancerous cell of mucepidermoid origin and the inhibition of the translation of the Mect1-MAML2 chimeric gene results in the inhibition of the cancerous cell.

53. (Previously Presented) The method of claim 52, wherein the cancerous cell is in a gland.

54. (Previously Presented) The method of claim 53, wherein the gland is a salivary gland.

55. (Previously Presented) A method of inhibiting the translation of a Mect1-MAML2 chimeric gene in a cell comprising contacting the cell expressing the Mect1-

MAML2 chimeric gene with the composition of claim 16, whereupon the translation of the Mect1-MAML2 chimeric gene in the cell is inhibited.

56. (Previously Presented) The method of claim 55, wherein the cell comprises a t(11;19) translocation, wherein the translocation results in a Mect1-MAML2 chimeric gene.

57. (Previously Presented) The method of claim 55, wherein the cell is in a host.

58. (Previously Presented) The method of claim 57, wherein the host is a mammal.

59. (Previously Presented) The method of claim 58, wherein the mammal is a human.

60. (Previously Presented) The method of claim 55, wherein the cell is a cancerous cell of mucepidermoid origin and the inhibition of the translation of the Mect1-MAML2 chimeric gene results in the inhibition of the cancerous cell.

61. (Previously Presented) The method of claim 60, wherein the cancerous cell is in a gland.

62. (Previously Presented) The method of claim 61, wherein the gland is a salivary gland.

63.-66. (Canceled)

67. (Previously Presented) The composition of claim 16, wherein the nucleic acid is in a vector.

68. (Previously Presented) The composition of claim 67, wherein the vector is a plasmid.

69. (Previously Presented) The composition of claim 67, wherein the vector is a viral vector.

70. (Previously Presented) The composition of claim 69, wherein the viral vector is an adenoviral vector.

71. (New) An *in vitro* method of inhibiting the translation of a Mect1-MAML2 chimeric gene in a cell comprising contacting the cell expressing the Mect1-MAML2 chimeric gene with the composition of claim 6, whereupon the translation of the Mect1-MAML2 chimeric gene in the cell is inhibited.

72. (New) An *in vitro* method of inhibiting the translation of a Mect1-MAML2 chimeric gene in a cell comprising contacting the cell expressing the Mect1-MAML2 chimeric gene with the composition of claim 16, whereupon the translation of the Mect1-MAML2 chimeric gene in the cell is inhibited.